IMMUCISION BIOTHERAPEUTICS
ImmuCision Biotherapeutics, LLC, is a privately owned biotechnology company.
IMMUCISION BIOTHERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2017-01-01
Address:
Baltimore, Maryland, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
2 M USD
Similar Organizations
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Current Employees Featured
Founder
More informations about "ImmuCision Biotherapeutics"
ImmuCision Biotherapeutics - Crunchbase Company Profile
ImmuCision Biotherapeutics focuses on the research and clinical development of immune cell-based therapies for human cancer. They are the development of cell-based immunotherapy …See details»
Human dendritic cell engineering technology - immucision.com
Immucision Biotherapeutics Immucision Biotherapeutics Immucision Biotherapeutics. Located at BioPark, University of Maryland, Baltimore, Maryland, the United States of America. Read …See details»
ImmuCision Biotherapeutics, LLC | UM BioPark
ImmuCision Biotherapeutics, LLC, is a privately owned biotechnology company committed to the development of cell-based immunotherapy for human cancer. ImmuCision utilizes an …See details»
ImmuCision BioTherapeutics Receives Quick Financial Backing, …
Sep 5, 2018 ImmuCision BioTherapeutics (ICBT) was established to commercialize and develop dendritic cell-based immunotherapy technologies that have been established at the Institute of …See details»
Immunotherapy startup moves into the University of Maryland …
Sep 6, 2018 After a pair of key milestones this year, a startup working on a new way to treat cancer is opening an office in Baltimore city. ImmuCision BioTherapeutics is taking office and …See details»
ImmuCision Biotherapeutics - Funding, Financials, Valuation
ImmuCision Biotherapeutics develops immunotherapy technologies for cancer treatment.See details»
Technical.ly: Immunotherapy Startup Moves into the University of ...
ImmuCision BioTherapeutics made the move after securing funding and validation for its work with dendritic cells – all this year.After a pair of key milestones this year, a startup working on …See details»
ImmuCision BioTherapeutics Receives Quick Financial Backing, …
Published 9/5/18 on PR Newswire. BALTIMORE, Sept. 5, 2018 /PRNewswire/ — The University of Maryland (UM) BioPark and UM Ventures announced today that ImmuCision …See details»
ImmuCision BioTherapeutics Receives Financial Backing, Locates in ...
M2 PHARMA-September 6, 2018-ImmuCision BioTherapeutics Receives Financial Backing, Locates in University of Maryland BioPark (C)2018 M2 COMMUNICATIONS - The University …See details»
ImmuCision Biotherapeutics - Products, Competitors, Financials ...
Use the CB Insights Platform to explore ImmuCision Biotherapeutics's full profile. ImmuCision Biotherapeutics - Products, Competitors, Financials, Employees, Headquarters Locations …See details»
Immucision Biotherapeutics, LLC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Immucision Biotherapeutics, LLC of Baltimore, MD. Get the latest business insights from Dun & Bradstreet.See details»
ImmuCision Biotherapeutics - Contacts, Employees, Board …
Organization. ImmuCision Biotherapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. …See details»
ImmuCision BioTherapeutics Receives Quick Financial Backing, …
BALTIMORE, Sept. 5, 2018 /PRNewswire/ -- The University of Maryland (UM) BioPark and UM Ventures announced today that ImmuCision BioTherapeutics (ICBT), a UM, Baltimore startup …See details»
PIPELINE - immucision.com
Immucision Biotherapeutics focuses on research and cancer therapy using the proprietary engineered dendritic cell technologySee details»
Immusoft Announces FDA Clearance of IND Application for ISP …
Sep 1, 2022 SEATTLE–(BUSINESS WIRE)–Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that the U.S. …See details»
Hua Cheng - Founder and Chief Scientist @ ImmuCision …
Hua Cheng is the Founder and Chief Scientist at Immucision Biotherapeutics and attended New York University School of Medicine. Search Crunchbase. Start Free Trial . Chrome Extension. …See details»
ImmunityBio Announces Completion of $470 Million Post
Dec 20, 2021 ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine …See details»
ImmuCision BioTherapeutics Receives Quick Financial Backing
BALTIMORE, Sept. 5, 2018 /PRNewswire/ -- University of Maryland BioPark and UM Ventures announced today that ImmuCision BioTherapeutics (ICBT), a UM, Baltimore startup company …See details»
100 years of Bacillus Calmette–Guérin immunotherapy: from
Jun 15, 2021 The Bacillus Calmette–Guérin (BCG) vaccine has been used since 1921 to prevent tuberculosis (TB) and is considered to be the world’s most widely used vaccine 1.In 2002, an …See details»